Fig. 1 · Structure

Documents & Downloads

ICG-001

Cat. No. A11039 CAS 780757-88-2

Wnt/beta-catenin inhibitor

ICG-001 is a specific inhibitor of Wnt/β-catenin signaling pathway that inhibits β-catenin/cyclic AMP response element-binding (CREB) protein transcription (IC50=3 microM) .

In Stock

Publications for ICG-001

8 publications citing this product

  1. Hong Gao, .et al. , Sci Rep, 2024, Oct 15;14(1):24182 PMID: 39406776
  2. Yun-Sheng Chen, .et al. , Research Square, 2024, August 16th
  3. Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
  4. Seonmin Choi, .et al. , Yonsei Med J, 2021, Nov;62(11):1042-1051 PMID: 34672138
  5. Jasper C.Munro, .et al. , Livest Sci, 2019, 229 (2019) 159-169
  6. Kim JH, .et al. , Cell Rep, 2019, May 14;27(7):2105-2118.e5 PMID: 31091449
  7. Yamaoka R, .et al. , J Surg Oncol, 2018, Sep;118(4):664-674 PMID: 30196535
  8. Aida Y, .et al. , In Vitro Cell Dev Biol Anim, 2018, Jun;54(6):468-476 PMID: 29785536

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

ICG-001 is used to investigate β-catenin-dependent transcription. In the original SW480 reporter study, its reported TOPFLASH IC50 was 3 μM, with no effect on the mutated-site FOPFLASH control. In a purified-fragment assay, 100 μM ICG-001 disrupted CBP/β-catenin association while preserving p300/β-catenin association. These assay-specific results do not establish a binding affinity or universal selectivity across biological contexts. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
CBP (Cell-free assay) 3 μM

Cellular Effect

Cell Line Activity Value Description Reference
A549 GI50 6.1 μM Antiproliferative activity against human A549 cells after 72 hrs by MTT assay [PMID: 24950489]
HCT-116 IC50 38 μM Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay [PMID: 34382808]
HCT-116 IC50 38 μM Antiproliferative activity against beta-catenin signalling overexpressing human HCT-116 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay [PMID: 34270257]
HepG2 GI50 12.7 μM Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay [PMID: 24950489]
HT-29 IC50 10.8 μM Cytotoxicity against human HT-29 cells assessed as cell viability at 1.563 to 50 uM measured after 72 hrs by plate reader method [PMID: 34062253]
HT-29 GI50 17.2 μM Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay [PMID: 24950489]
HT-29 IC50 18.7 μM Inhibition of Wnt signaling in human HT29 cells assessed as inhibition of beta-catenin-mediated Tcf/Lef transcriptional activity after 24 hrs by dual luciferase reporter gene assay relative to control [PMID: 24950489]
LoVo GI50 15.6 μM Antiproliferative activity against human LoVo cells after 72 hrs by MTT assay [PMID: 24950489]
MCF-10A IC50 21 μM Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition measured after 72 hrs by MTS assay [PMID: 34382808]
MCF-10A IC50 21 μM Cytotoxicity against human MCF-10A cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay [PMID: 34270257]
MDA-MB-231 IC50 7.2 μM Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay [PMID: 34382808]
MDA-MB-231 IC50 7.2 μM Antiproliferative activity against beta-catenin signalling overexpressing human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay [PMID: 34270257]
MDA-MB-468 IC50 31 μM Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay [PMID: 34382808]
MDA-MB-468 IC50 31 μM Antiproliferative activity against beta-catenin signalling overexpressing human MDA-MB-468 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay [PMID: 34270257]
SW480 IC50 1.3 μM Inhibition of CBP binding to beta-casein in human SW480 cells by immunoblot analysis [PMID: 23232060]
SW480 IC50 6.1 μM Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay [PMID: 34382808]
SW480 IC50 6.1 μM Antiproliferative activity against beta-catenin signalling overexpressing human SW480 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay [PMID: 34270257]

17 records · Scroll to view more

ICG-001 Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of ICG-001 from 3 published references. In vitro models include purified CBP, p300, and β-catenin; SW480 human colorectal carcinoma cells.

ICG-001 In Vitro Studies

In four pancreatic cancer cell lines, 10 μM ICG-001 induced G1 arrest at 24 h. Annexin V/PI analysis at 48 h showed a significant apoptosis increase only in L3.6pl. CTNNB1 knockdown did not reproduce G1 arrest in AsPC-1, indicating that the cell-cycle response cannot simply be equated with β-catenin inhibition. [2]

ICG-001 increased migration in KHOS, MG63 and 143B osteosarcoma cells in an 8 h Boyden-chamber assay after 24 h pretreatment at 10 μM. Real-time assays in KHOS and 143B showed increased migration at 8 h but no significant difference at 24 h. These results argue against assuming a uniform anti-migratory effect. [3]

Purified CBP/β-catenin interaction assay

Biochemical assay · Purified CBP(1–111), p300(1–111), and β-catenin(647–781) [1]

At 100 μM, ICG-001 disrupted the CBP/β-catenin complex in the reported assay while the p300/β-catenin complex was retained. This single-concentration assay does not establish a binding Kd or universal target selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CBP or p300 retained in β-catenin complexesQualitative immunoblot comparison CBP interaction disrupted; p300 interaction retained[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM
Method
Challenge of preformed protein complexes followed by anti-His immunoblot
Reported limits
Challenge duration and solvent for this purified-protein panel are not specified in the acquired caption/text.
Methods and source locations

Compound reported in the paper: ICG-001; Compound label in the paper: ICG-001

Evidence applies to the paper’s ICG-001 material and stated assay/model. Salt form, stereochemical purity and equivalence to an Adooq lot were not established.

Results: ICG-001 Specifically Interacts with CBP; Figure 2B and caption

CBP or p300 retained in β-catenin complexes: Purified CBP or p300 fragments (5 μg) with β-catenin fragment (5 μg); paired no-ICG-001 lanes — Results: ICG-001 Specifically Interacts with CBP; Figure 2B and caption

β-catenin/TCF reporter inhibition

Cell-based study · SW480 human colorectal carcinoma cells [1]

ICG-001 inhibited TOPFLASH with a reported IC50 of 3 μM, whereas the mutated-site FOPFLASH reporter was unaffected in the tested series. The IC50 is a cellular reporter endpoint, not a CBP binding constant.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TOPFLASH activityReported IC50 3 μM[1]
Mutated TCF-site FOPFLASH activityReporter control No effect reported over the tested series[1]

Literature-Reported Treatment Conditions

Treatment concentration
Figure 1B-C: 1.6, 3.1, 12, 25, 50 and 100 μM
Method
TOPFLASH/FOPFLASH dual-luciferase reporter assays
Reported limits
Treatment duration and solvent for Figure 1B-C are not specified in the acquired methods/caption; 24-hour conditions from Figure 3 were not borrowed.
Methods and source locations

Compound reported in the paper: ICG-001; Compound label in the paper: ICG-001

Evidence applies to the paper’s ICG-001 material and stated assay/model. Salt form, stereochemical purity and equivalence to an Adooq lot were not established.

Results: ICG-001 Antagonizes β-Catenin/TCF Transcription; Figure 1B-C; Methods: Transfection and Luciferase Assays

TOPFLASH activity: Dual luciferase; transfection normalization with pRL-null. Methods describe the mean of two independent experiments performed in duplicate. — Results: ICG-001 Antagonizes β-Catenin/TCF Transcription; Figure 1B-C; Methods: Transfection and Luciferase Assays

Mutated TCF-site FOPFLASH activity: Figure 1C versus no-compound baseline — Results: ICG-001 Antagonizes β-Catenin/TCF Transcription; Figure 1B-C; Methods: Transfection and Luciferase Assays

PDAC cell-cycle arrest and apoptosis controls

Cell-based study · AsPC-1, L3.6pl, PANC-1 and MiaPaCa-2 human pancreatic cancer cells; CTNNB1 perturbation comparison in AsPC-1 [2]

ICG-001 induced G1 arrest in all four lines. Apoptosis by annexin V/PI increased significantly only in L3.6pl. CTNNB1 knockdown did not reproduce G1 arrest in AsPC-1, limiting attribution of the cell-cycle response solely to β-catenin inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell-cycle distributionQualitative direction G1 arrest in all four lines; CTNNB1 knockdown alone did not induce G1 arrest in AsPC-1[2]
Annexin V/PI-positive apoptosisStatistical comparison with vehicle Significant increase in L3.6pl; no significant increase in AsPC-1, PANC-1 or MiaPaCa-2[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM ICG-001
Exposure duration
24 h for cell-cycle and protein assays; 48 h for annexin V/PI and CTNNB1 comparison
Method
Flow cytometry and immunoblot
Vehicle
DMSO
Co-treatment
CTNNB1 or control siRNA (20 nM) comparison; staurosporine 500 nM is a separate apoptosis-positive control, not an ICG-001 combination efficacy result.
Reported limits
No exact DMSO percentage given for these cellular panels. Cell lines were not subsequently authenticated after receipt.
Methods and source locations

Compound reported in the paper: ICG-001; Compound label in the paper: ICG-001

Evidence applies to the paper’s ICG-001 material and stated assay/model. Salt form, stereochemical purity and equivalence to an Adooq lot were not established.

Figure 4A-D and caption; Results: ICG-001 induces G1 arrest and has variable effects on Wnt/β-catenin signaling; Methods: Cell growth, proliferation and apoptosis assays, Gene Knockdown

Cell-cycle distribution: Propidium iodide flow cytometry; Figure 4C at 24 h and Figure 4D at 48 h. Figure 4D caption reports >75% β-catenin knockdown. One representative experiment of three replicates. — Figure 4A-D and caption; Results: ICG-001 induces G1 arrest and has variable effects on Wnt/β-catenin signaling; Methods: Cell growth, proliferation and apoptosis assays, Gene Knockdown

Annexin V/PI-positive apoptosis: Annexin V/PI at 48 h, Figure 4B; separate 24 h immunoblots include staurosporine positive control and tubulin loading control (4A). — Figure 4A-D and caption; Results: ICG-001 induces G1 arrest and has variable effects on Wnt/β-catenin signaling; Methods: Cell growth, proliferation and apoptosis assays, Gene Knockdown

Increased osteosarcoma cell migration

Cell-based study · Human KHOS, MG63 and 143B osteosarcoma cells [3]

After 24 h pretreatment with 10 μM ICG-001, Boyden-chamber migration increased in all three lines at the 8 h endpoint. Impedance-based migration increased at 8 h in KHOS and 143B but no longer differed significantly at 24 h. This is adverse, context-dependent evidence.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Migrated cells relative to DMSO controlReported fold change KHOS 3-fold; MG63 1.8-fold; 143B 4-fold[3]
Impedance migration cell index relative to vehicleQualitative time dependence Increased at 8 h in KHOS and 143B; no significant difference at 24 h[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
24 h pretreatment; migration monitored for 8 h by Boyden chamber or up to 24 h by impedance
Method
Boyden chamber and xCELLigence real-time migration
Vehicle
DMSO
Reported limits
Exact DMSO percentage and stereochemical purity not reported in the acquired cellular methods.
Methods and source locations

Compound reported in the paper: ICG-001; Compound label in the paper: ICG-001

Evidence applies to the paper’s ICG-001 material and stated assay/model. Salt form, stereochemical purity and equivalence to an Adooq lot were not established.

Results 2.3; Figure 5a-c and caption; Methods 4.1, 4.11-4.12, 4.15

Migrated cells relative to DMSO control: 8 h Boyden assay after 24 h pretreatment; DMSO set to 100%. Figure 5a means ± SD; KHOS n=3, MG63 n=2, 143B n=3, each performed in duplicate. — Results 2.3; Figure 5a-c and caption; Methods 4.1, 4.11-4.12, 4.15

Impedance migration cell index relative to vehicle: Figure 5b means ± SEM from three independent experiments, each in duplicate. MG63 could not be evaluated using this assay because of low migration. — Results 2.3; Figure 5a-c and caption; Methods 4.1, 4.11-4.12, 4.15

ICG-001 In Vivo Studies

In an AsPC-1 orthotopic pancreatic xenograft model, intraperitoneal ICG-001 at 5 mg/kg, 6 days/week for 8 weeks, improved survival relative to vehicle (HR=0.207, 95% CI 0.079–0.543; P=0.001). The combination with gemcitabine did not significantly improve survival relative to gemcitabine alone. Endpoint dissemination scores were similar across treatment groups. These findings are specific to this mouse model and regimen. [2]

Orthotopic pancreatic xenograft survival

Animal study · Six-week-old female athymic nude mice bearing AsPC-1 orthotopic pancreatic tumors [2]

ICG-001 prolonged survival relative to vehicle. Combined ICG-001/gemcitabine improved survival relative to ICG-001 alone but did not significantly improve survival relative to gemcitabine alone. Tumor dissemination scores at endpoint were not different among groups.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Survival: ICG-001 versus vehicleCox hazard ratio (95% CI) HR=0.207, 95% CI: 0.079–0.543, P=0.001[2]
Survival: combination versus gemcitabine aloneCox hazard ratio (95% CI) HR=0.608, 95% CI: 0.254–1.455, P=0.66[2]
Endpoint dissemination and on-treatment tumor transcriptsQualitative comparison No dissemination-score differences among four arms; MMP7 decreased with ICG-001, BIRC5 and AXIN2 did not significantly change[2]

Conditions shared by the study groups

Route
Intraperitoneal
Treatment course
8 weeks, beginning 10 days after implantation; subsequent observation up to post-surgery day 120
Vehicle
20% PEG300, 5% solutol, 3.75% dextrose, 1% DMSO in PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
VehicleVehicle arm; additional single-agent arms for combination comparisonComparator for survival; dissemination at endpoint comparable to other arms.[2]
ICG-001
5 mg/kg
Vehicle arm; additional single-agent arms for combination comparisonLower hazard than vehicle: HR=0.207 (95% CI 0.079–0.543), P=0.001.[2]
Gemcitabine
25 mg/kg
Vehicle arm; additional single-agent arms for combination comparisonLower hazard than vehicle: HR=0.123 (95% CI 0.045–0.334), P<0.001.[2]
ICG-001 plus gemcitabine
ICG-001 5 mg/kg + gemcitabine 25 mg/kg
Vehicle arm; additional single-agent arms for combination comparisonVersus ICG-001: HR=0.360 (95% CI 0.152–0.848), P=0.02; versus gemcitabine: HR=0.608 (95% CI 0.254–1.455), P=0.66.[2]
Vehicle
Model: Female athymic nude mice with AsPC-1 orthotopic tumors; n=12
Reported limits: Injection frequency of vehicle-only arm is not explicitly separately stated.
ICG-001
Model: Female athymic nude mice with AsPC-1 orthotopic tumors; n=12
Frequency: 6 days/week
Gemcitabine
Model: Female athymic nude mice with AsPC-1 orthotopic tumors; n=11
Frequency: 2 days/week
ICG-001 plus gemcitabine
Model: Female athymic nude mice with AsPC-1 orthotopic tumors; n=12
Frequency: ICG-001 6 days/week; gemcitabine 2 days/week
Methods and source locations

Compound reported in the paper: ICG-001; Compound label in the paper: ICG-001

Evidence applies to the paper’s ICG-001 material and stated assay/model. Salt form, stereochemical purity and equivalence to an Adooq lot were not established.

Figure 2A-E; Results: ICG-001 inhibits in vivo PDAC tumor growth; Methods: Orthotopic Xenograft Tumor Assay, Statistics

Survival: ICG-001 versus vehicle: Cox proportional hazards; mice randomized, vehicle n=12 and ICG-001 n=12. Humane endpoints: body condition score 2 or palpable tumor diameter 1.5 cm. — Figure 2A-E; Results: ICG-001 inhibits in vivo PDAC tumor growth; Methods: Orthotopic Xenograft Tumor Assay, Statistics

Survival: combination versus gemcitabine alone: Gemcitabine n=11; combination n=12. Comparison was not statistically significant. — Figure 2A-E; Results: ICG-001 inhibits in vivo PDAC tumor growth; Methods: Orthotopic Xenograft Tumor Assay, Statistics

Endpoint dissemination and on-treatment tumor transcripts: Figure 2B,D; qPCR normalized to ACTB in tumors harvested during treatment, a subset distinct from full survival cohorts. — Figure 2A-E; Results: ICG-001 inhibits in vivo PDAC tumor growth; Methods: Orthotopic Xenograft Tumor Assay, Statistics

Vehicle · Figure 2A-E; Results: ICG-001 inhibits in vivo PDAC tumor growth; Methods: Orthotopic Xenograft Tumor Assay, Statistics

ICG-001 · Figure 2A-E; Results: ICG-001 inhibits in vivo PDAC tumor growth; Methods: Orthotopic Xenograft Tumor Assay, Statistics

Gemcitabine · Figure 2A-E; Results: ICG-001 inhibits in vivo PDAC tumor growth; Methods: Orthotopic Xenograft Tumor Assay, Statistics

ICG-001 plus gemcitabine · Figure 2A-E; Results: ICG-001 inhibits in vivo PDAC tumor growth; Methods: Orthotopic Xenograft Tumor Assay, Statistics

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 780757-88-2
Alternate CAS 847591-62-2
Applications Wnt/beta-catenin inhibitor
Formula C33H32N4O4
Molecular Weight 548.6
SMILES
C1CN([C@H]2CN(C(=O)[C@@H](N2C1=O)CC3=CC=C(C=C3)O)CC4=CC=CC5=CC=CC=C54)C(=O)NCC6=CC=CC=C6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 99 mg/mL (180.45 mM)
Water Insoluble
Ethanol 10 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
2% DMSO+50% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

ICG-001 Research References

  1. [1] Katayoon H. Emami, Cu Nguyen, Hong Ma, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription. Proceedings of the National Academy of Sciences of the United States of America (2004). PMID: 15314234 DOI: 10.1073/pnas.0404875101 Source material
  2. [2] Arensman MD, Telesca D, Lay AR, et al. The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Molecular cancer therapeutics (2014). PMID: 25082960 DOI: 10.1158/1535-7163.mct-13-1005 Source material
  3. [3] Danieau G, Morice S, Renault S, et al. ICG-001, an Inhibitor of the β-Catenin and cAMP Response Element-Binding Protein Dependent Gene Transcription, Decreases Proliferation but Enhances Migration of Osteosarcoma Cells. Pharmaceuticals (Basel, Switzerland) (2021). PMID: 34062831 DOI: 10.3390/ph14050421 Source material

Publications

8 publications citing this product

  1. Hong Gao, .et al. , Sci Rep, 2024, Oct 15;14(1):24182 PMID: 39406776
  2. Yun-Sheng Chen, .et al. , Research Square, 2024, August 16th
  3. Bopei Cui, .et al. , Signal Transduct Target Ther, 2023, Sep 25;8(1):366 PMID: 37743418
  4. Seonmin Choi, .et al. , Yonsei Med J, 2021, Nov;62(11):1042-1051 PMID: 34672138
  5. Jasper C.Munro, .et al. , Livest Sci, 2019, 229 (2019) 159-169
  6. Kim JH, .et al. , Cell Rep, 2019, May 14;27(7):2105-2118.e5 PMID: 31091449
  7. Yamaoka R, .et al. , J Surg Oncol, 2018, Sep;118(4):664-674 PMID: 30196535
  8. Aida Y, .et al. , In Vitro Cell Dev Biol Anim, 2018, Jun;54(6):468-476 PMID: 29785536

Added to your cart

View Cart Checkout
Loading...